Literature DB >> 2573328

P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms.

A Pfefferbaum1, J M Ford, P M White, W T Roth.   

Abstract

Eighteen schizophrenics who were not taking medication, 13 schizophrenics who were taking medication, and 37 age-matched controls were tested with event-related potential paradigms designed to elicit P3 response automatically or effortfully (ie, with a choice reaction time task). Electroencephalograms were recorded from the 19 standard 10-20 electrode sites. Compared with controls, both groups of schizophrenics had reduced P3 amplitudes for both effortful and automatic paradigms. P3 latencies were delayed relative to controls for the medication-taking schizophrenics in the effortful paradigms. Negative symptoms derived from the Brief Psychiatric Rating Scale within 1 week of event-related potential testing correlated negatively with both auditory and visual P3 amplitude in the subjects who were not taking medication. There was no evidence that P3 is smaller over left temporal electrode sites in schizophrenics, as has been reported by others. P3 amplitude reduction in schizophrenia is a robust psychobiological phenomenon that is present regardless of medication status or task demands.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573328     DOI: 10.1001/archpsyc.1989.01810110077011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  49 in total

1.  Button-pressing affects P300 amplitude and scalp topography.

Authors:  D F Salisbury; B Rutherford; M E Shenton; R W McCarley
Journal:  Clin Neurophysiol       Date:  2001-09       Impact factor: 3.708

2.  ERP generator patterns in schizophrenia during tonal and phonetic oddball tasks: effects of response hand and silent count.

Authors:  Jürgen Kayser; Craig E Tenke; Roberto Gil; Gerard E Bruder
Journal:  Clin EEG Neurosci       Date:  2010-10       Impact factor: 1.843

3.  Clinical significance of auditory target P300 subcomponents in psychosis: Differential diagnosis, symptom profiles, and course.

Authors:  Greg Perlman; Dan Foti; Felicia Jackson; Roman Kotov; Eduardo Constantino; Greg Hajcak
Journal:  Schizophr Res       Date:  2015-04-29       Impact factor: 4.939

4.  The effect of laterality of stimulus presentation on auditory P300 topography in schizophrenia.

Authors:  F Bolsche; D J MacCrimmon; S Kropf
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

5.  Projection onto centroids difference vectors: a new approach to determine between group topographical differences, applied to P3 amplitude in schizophrenia.

Authors:  A R Haig; E Gordon
Journal:  Brain Topogr       Date:  1995       Impact factor: 3.020

6.  Event-related potential P300 microstate topography during visual one- and two-dimensional tasks in chronic schizophrenics.

Authors:  K Kochi; T Koenig; W K Strik; D Lehmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

7.  The predictive value of P300-amplitudes in the course of schizophrenic disorders.

Authors:  W K Strik; T Dierks; H Kulke; K Maurer; A Fallgatter
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Increasing stimulus duration can normalize late-positive event related potentials in people with schizophrenia: Possible implications for understanding cognitive deficits.

Authors:  Bruce E Wexler; Satoru Ikezawa; Silvia Corbera
Journal:  Schizophr Res       Date:  2014-08-03       Impact factor: 4.939

9.  Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder.

Authors:  Daniel H Mathalon; Ralph E Hoffman; Todd D Watson; Ryan M Miller; Brian J Roach; Judith M Ford
Journal:  Front Hum Neurosci       Date:  2010-01-29       Impact factor: 3.169

10.  Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Karsten Heekeren; Jörg Daumann; Anna Neukirch; Carsten Stock; Wolfram Kawohl; Christine Norra; Till D Waberski; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-05-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.